{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036979","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2026-08-11T11:05:26+00:00","discovered_at":"2026-08-11T11:10:00.404220+00:00","generated_at":"2026-08-11T11:10:32.598963+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Xtant Q2 revenue down 35% to $23M, net loss $9.4M, cuts FY guidance","bullets":["Revenue $23.0M vs $35.4M YoY; net loss $9.4M vs income $3.6M.","Adjusted EBITDA loss $2.7M vs +$6.9M; gross margin 57.9% vs 68.6%.","FY2026 revenue guidance cut to $99-103M from $101-105M.","Exclusive U.S. distribution deal with Dilon for HEMOBLAST Bellows; hired ~20-person sales team.","Cash $9.9M, debt $23.0M, revolver availability $0.7M as of June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036979","json":"https://secwatch.observer/filing/0001493152-26-036979.json","markdown":"https://secwatch.observer/filing/0001493152-26-036979.md","text":"https://secwatch.observer/filing/0001493152-26-036979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226036979/0001493152-26-036979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226036979/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:10:32.598963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}